| Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma VJ Spanswick, C Craddock, M Sekhar, P Mahendra, P Shankaranarayana, ... Blood, The Journal of the American Society of Hematology 100 (1), 224-229, 2002 | 163 | 2002 |
| Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics S Paneesha, A McManus, R Arya, N Scriven, T Farren, T Nokes, S Bacon, ... Thrombosis and Haemostasis 103 (02), 338-343, 2010 | 125 | 2010 |
| Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism L Knowlson, S Bacchu, S Paneesha, A McManus, K Randall, P Rose Journal of Clinical Pathology 63 (9), 818-822, 2010 | 96 | 2010 |
| Peripheral blood stem cell transplantation for POEMS syndrome KS Peggs, S Paneesha, PD Kottaridis, RK Chakraverty, G Tobias, ... Bone marrow transplantation 30 (6), 401-404, 2002 | 75 | 2002 |
| Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial AK McMillan, EH Phillips, AA Kirkwood, S Barrans, C Burton, S Rule, ... Annals of Oncology 31 (9), 1251-1259, 2020 | 48 | 2020 |
| Stem cell transplantation for chronic lymphocytic leukaemia S Paneesha, DW Milligan British journal of haematology 128 (2), 145-152, 2005 | 39 | 2005 |
| Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic … E Nikolousis, S Robinson, S Nagra, C Brookes, F Kinsella, S Tauro, ... Leukemia research 37 (5), 561-565, 2013 | 37 | 2013 |
| Does ambulation modify venous thromboembolism risk in acutely ill medical patients? AN Amin, F Girard, MM Samama Thrombosis and haemostasis 104 (11), 955-961, 2010 | 37 | 2010 |
| High D‐dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes S Paneesha, E Cheyne, K French, S Bacchu, A Borg, P Rose British journal of haematology 135 (1), 85-90, 2006 | 35 | 2006 |
| The P2X7 receptor gene polymorphism 1513 A→ C has no effect on clinical prognostic markers and survival in multiple myeloma S Paneesha, J Starczynski, C Pepper, J Delgado, L Hooper, C Fegan, ... Leukemia & lymphoma 47 (2), 281-284, 2006 | 25 | 2006 |
| Burkitt's lymphoma: single‐centre experience with modified BFM protocol E Harris, S Paneesha, N Jackson, L Jones, P Mahendra Clinical & Laboratory Haematology 24 (2), 111-114, 2002 | 23 | 2002 |
| The SDF-1 G> A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia NC Pemberton, S Paneesha, L Hiller, J Starczynski, L Hooper, C Pepper, ... Leukemia & lymphoma 47 (7), 1239-1244, 2006 | 21 | 2006 |
| Ncri petrea trial: a phase 3 evaluation of pet‐guided, response‐adapted therapy in patients with previously untreated, advanced‐stage, high‐tumour‐burden follicular lymphoma AR Pettitt, S Barrington, N Kalakonda, UT Khan, R Jackson, S Carruthers, ... Hematological Oncology 37, 67-68, 2019 | 14 | 2019 |
| Low rates of CNS relapse in high risk DLBCL patients treated with R-CODOX-M and R-IVAC: results from a phase 2 UK NCRI/Bloodwise trial EH Phillips, AA Kirkwood, A Lawrie, S Rule, R Patmore, R Pettengell, ... Blood 128 (22), 1855, 2016 | 12 | 2016 |
| Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy H Narayan, D Bandyopadhyay, K Schmidt, N Chachlani, M Hughes, ... Clinical & Laboratory Haematology 27 (6), 405-408, 2005 | 12 | 2005 |
| High D-dimer level at presentation in patients with venous thrombosis is a marker for malignancy S Paneesha, E Cheyne, K French, J Delgado, A Borg, P Rose Haematologica 90 (12_Suppl), ELT08-ELT08, 2005 | 10 | 2005 |
| for the VERITY investigatorsFrequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics S Paneesha, A McManus, R Arya, N Scriven, T Farren, T Nokes, S Bacon, ... Thromb Haemost 103 (2), 338-343, 2010 | 8 | 2010 |
| R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial A Kühnl, C Peckitt, B Patel, KM Ardeshna, MP Macheta, J Radford, ... Annals of hematology 99, 105-112, 2020 | 7 | 2020 |
| Favourable outcomes with R-CODOX-M/R-IVAC across all subgroups of aggressive high grade B-cell lymphoma: pathology and updated survival results from a phase 2 UK NCRI/LLR trial E Phillips, C Burton, A Kirkwood, S Barrans, A Lawrie, S Rule, R Patmore, ... EHA Library 214487, S1548, 2018 | 7 | 2018 |
| Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI … P Hillmen, DA Cairns, AJC Bloor, D Allsup, K Cwynarski, A Pettitt, ... Blood 142, 631, 2023 | 6 | 2023 |
